Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease). The peptide is also under evaluation for potential prophylactic therapeutic benefits as well.
HT-002 is at the preclinical stage of development.
In June 2020, Hoth entered a research agreement with Virginia Commonwealth University (“VCU”) to develop and optimize the novel peptide therapeutic. Positive preclinical results were achieved in Q1 2021.
Further preclinical studies with SARS-CoV-2 variants to be initiated in Q2 2021 followed by delivery proof of concept studies later in the year.